Table 1. Pancreatic cancer clinicopathological parameters and their correlation with TTP expression.
Features | NO. of patients(%) | Low expression of TTP(%) | P value |
---|---|---|---|
Gender | |||
Male | 57(63.3%) | 47(82.4%) | 0.295 |
Female | 33(36.7%) | 24(72.0%) | |
Location | |||
Head | 37(41.1%) | 31(83.8%) | 0.435 |
Body and Tail | 53(58.9%) | 40(75.5%) | |
Age, years | |||
<60 | 41(45.6%) | 28(68.3%) | 0.037* |
>60 | 49(54.4%) | 43(87.5%) | |
Tumor Size, cm | |||
<3 | 40(44.4%) | 26(65.0%) | 0.008* |
>3 | 50(55.6%) | 45(90.0%) | |
Differentiation | |||
Well | 19(21.1%) | 10(52.6%) | 0.004* |
Moderate/Poor | 71(78.9%) | 61(85.9%) | |
pT stage | |||
T1 | 16(17.8%) | 6(37.5%) | <0.001* |
T2 | 55(61.1%) | 48(87.2%) | |
T3 | 19(21.1%) | 17(89.4%) | |
pN stage | |||
Negative | 51(56.7%) | 35(68.6%) | 0.008* |
Positive | 39(43.3%) | 36(92.3%) | |
TNM stage | |||
I | 40(44.4%) | 24(60.0%) | <0.001* |
II-IV | 50(55.6%) | 47(94.0%) |
p<0.05, statistically significant.